|
Market Closed -
Nasdaq
21:00:00 22/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 1.130 USD | -3.42% |
|
+0.89% | -51.50% |
| 08-12 | Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SPERO THERAPEUTICS, INC. | Bio Therapeutic Drugs | -3.42% | +0.89% | -51.50% | -52.32% | -93.25% | 68.13M |  |  | |
- Stock Market
- Stocks
- SPRO Stock
- Charts Spero Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
